Moderna Inc. has recently garnered significant attention with a series of developments in its
mRNA vaccine technology. The U.S. Food and Drug Administration (FDA) has given a green light to
Moderna's mRESVIA, marking a new era in the field of mRNA vaccines. This is not only significant for Moderna, but it's paving the way for mRNA vaccines in various fields, from infectious diseases to cancer therapeutics. Furthermore, bird flu vaccine trials from Moderna are likely to receive funding by the U.S. government. This comes as a part of broader efforts by Moderna to expand their mRNA vaccines into several other infectious diseases. Moderna’s mRNA drug candidate has also made it into the FDA’s Accelerator Program for ailments classified under rare diseases.
Melanoma Vaccine trials by Moderna, have shown promising results, marking yet another potential milestone in cancer therapeutics. Offering further testament to the potential of mRNA technology, Quantum Researchers from IBM have partnered with Moderna for a key development stage in RNA-based therapeutic design. The mRNA technology, however, has been marked with a slight setback as Moderna halts mRNA plant buildout in Kenya due to uncertain vaccine demand.
Moderna MRNA News Analytics from Wed, 13 Sep 2023 07:00:00 GMT to Sun, 09 Jun 2024 11:07:31 GMT -
Rating 8
- Innovation 6
- Information 6
- Rumor -4
